Autres langues Biogen Inc.

Actions

BIIB

US09062X1037

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 24/09/2026			Varia. 5j.	Varia. 1 janv.
226,36 ^USD	-0,51%		+3,34%	+28,62%

23/09	Le développeur de médicaments basé sur l’IA Basecamp valorisé 800 millions de dollars après une levée de fonds de 140 millions	RE
17/09	Biogen publie les données pédiatriques de phase 3 sur l'EMPAVELI montrant une réduction de la protéinurie et une stabilisation de la fonction rénale chez les adolescents atteints de C3G ou de CI-MPGN primitive	CI

Autres langues

23/09	AI-based drug developer Basecamp valued at $800 million after $140 million funding round
23/09	Compañías que se deben tener muy en cuenta por técnico este miércoles en Wall Street
23/09	Ha llegado el momento de esta compañía del Nasdaq 100
23/09	Valores destacados al cierre del mercado norteamericano
17/09	Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
17/09	Biogen Publishes Phase 3 Pediatric EMPAVELI Data Showing Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3g or Primary IC-MPGN
16/09	Eisai and Biogen Receive Approval for LEQEMBI Pen Subcutaneous Formulation for Early Alzheimer?s Disease in Japan
11/09	Scholar Rock gets first FDA nod for rare muscle-wasting disease (September 11)
11/09	US FDA approves Scholar Rock's muscle weakness drug
11/09	Compañías que se deben tener muy en cuenta por técnico este viernes en Wall Street
11/09	Valores destacados al cierre del mercado norteamericano
08/09	Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
08/09	Eisai And Biogen Receive Approval For Leqembi Subcutaneous Formulation As Initiation Treatment For Early Alzheimer's Disease In China
04/09	Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
04/09	Compañías que se deben tener muy en cuenta por técnico este viernes en Wall Street
04/09	Eisai, Biogen Secure China's Nod for Self-Injection Version of Leqembi
04/09	Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
03/09	Compañías que se deben tener muy en cuenta por técnico este jueves en Wall Street
03/09	Valores destacados al cierre del mercado norteamericano
01/09	Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
01/09	Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
01/09	Eisai Issues Final Positive Recommendation Supporting Public Reimbursement Of LEQEMBI For Early Alzheimer'S Disease In Canada
25/08	Veeva Systems Secures Biogen, Regeneron Pharmaceuticals as New Vault CRM Clients
24/08	Biogen, Eisai's LEQEMBI IQLIK Now Available in US for Early Alzheimer's Disease